Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protein found in human gastric juice. First identified in the early 1990s by researchers at the University of Zagreb, BPC-157 has since become one of the most extensively studied regenerative peptides in preclinical research, with over 100 published studies examining its diverse biological effects.
The peptide's mechanism centers on its ability to modulate multiple growth factor systems simultaneously, including upregulation of vascular endothelial growth factor (VEGF), activation of the FAK-paxillin pathway, and nitric oxide (NO) system modulation. This multi-target approach distinguishes BPC-157 from single-pathway therapeutics and may explain its apparent efficacy across diverse tissue types including tendon, muscle, bone, ligament, nerve, and gastrointestinal epithelium.
Despite the volume of preclinical evidence, BPC-157 has not undergone rigorous human clinical trials and is not FDA-approved for any indication. The FDA has issued warning letters to companies marketing BPC-157 for human use. Nonetheless, it remains one of the most popular peptides in regenerative medicine research, with practitioners reporting anecdotal benefits for injury recovery, gut healing, and neuroprotection.
This comprehensive guide examines the current state of BPC-157 research, its proposed mechanisms of action, safety profile based on available data, and important considerations for anyone evaluating this peptide for potential therapeutic applications.
Quick facts
- Mechanism
- Multi-pathway regenerative peptide from gastric juice
- Primary use
- Tissue Repair & Gut Healing
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous injection or oral administration
- Typical results
- Accelerated tissue healing observed in animal models within 1β4 weeks
Chemical information
BPC-157 is a stable pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. With a molecular mass of 1,419.5 g/mol and the formula CββHββNββOββ, it is notably stable in human gastric juiceβa property unusual for peptides of this size. Its stability is attributed to the high proportion of proline residues, which create rigid turn structures resistant to enzymatic degradation.
How BPC-157 works
BPC-157 operates through a remarkably complex set of molecular pathways that converge on tissue protection and regeneration. Its primary mechanism involves modulation of the nitric oxide (NO) system, which plays a central role in vascular function, inflammation, and tissue repair. The peptide appears to restore NO homeostasis in damaged tissues, promoting angiogenesis (new blood vessel formation) and reducing inflammatory signaling cascades.
At the cellular level, BPC-157 activates the FAK-paxillin signaling pathway, which is critical for cell migration and wound closure. This pathway promotes fibroblast mobilization to injury sites, accelerating the deposition of collagen and extracellular matrix components necessary for structural tissue repair. Studies have demonstrated that BPC-157 can significantly accelerate tendon-to-bone healing and ligament repair in animal models.
The peptide also demonstrates significant interactions with the dopaminergic, serotonergic, and GABAergic neurotransmitter systems, which may explain its observed neuroprotective effects. In animal models of traumatic brain injury, BPC-157 has shown the ability to reduce cerebral edema, improve neurological outcomes, and protect against excitotoxic damage. Additionally, it appears to counteract the gastrointestinal side effects of NSAIDs and other drugs by strengthening the mucosal barrier.
BPC-157 has been shown to upregulate growth hormone receptor expression in tendon fibroblasts, enhance EGF receptor signaling in intestinal epithelial cells, and modulate the JAK-STAT pathway involved in immune regulation. This broad spectrum of molecular targets suggests that BPC-157 functions as a systemic protective agent rather than a single-pathway modulator.
- NO system modulation: Restores nitric oxide homeostasis in damaged tissues, promoting vasodilation and angiogenesis
- FAK-paxillin pathway: Activates focal adhesion kinase signaling to accelerate cell migration and wound closure
- VEGF upregulation: Stimulates vascular endothelial growth factor to promote new blood vessel formation at injury sites
- Neurotransmitter modulation: Interacts with dopamine, serotonin, and GABA systems for neuroprotective effects
- Growth factor receptor sensitization: Enhances GH receptor and EGF receptor signaling in target tissues
- Anti-inflammatory cascade: Reduces pro-inflammatory cytokines (TNF-Ξ±, IL-6) while preserving beneficial immune responses
Pharmacokinetics
BPC-157's pharmacokinetic profile in humans has not been formally characterized in published clinical trials. The following data is extrapolated from animal studies and in vitro experiments.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC) | High (estimated >80%) | Excellent absorption via subcutaneous route |
| Bioavailability (Oral) | Moderate (gastric-stable) | Unusually stable in gastric acid for a peptide |
| Half-life | Estimated 4β6 hours | May support twice-daily dosing protocols |
| Distribution | Systemic with tissue tropism | Appears to concentrate at sites of injury |
| Metabolism | Peptidase degradation | Standard peptide metabolism pathway |
| Onset of effects | 24β72 hours (animal models) | Rapid onset observed in tissue repair models |
Dosing & administration
BPC-157 dosing in preclinical research typically follows a weight-based protocol of 10 mcg/kg/day, which translates to approximately 500β750 mcg/day for an average adult when extrapolated from animal data. Practitioners commonly use doses ranging from 200β500 mcg administered once or twice daily via subcutaneous injection near the injury site.
Oral administration has also been studied, typically at higher doses (250β500 mcg taken on an empty stomach) due to expected first-pass effects, although BPC-157's unusual gastric stability may mitigate some bioavailability losses. Research protocols typically run for 4β8 weeks, with some practitioners extending to 12 weeks for chronic conditions.
It is critical to note that these dosing guidelines are derived from animal research extrapolation and anecdotal practitioner reportsβnot from controlled human clinical trials. No FDA-approved dosing exists for BPC-157, and any human use should be conducted under qualified medical supervision.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
BPC-157 has demonstrated a remarkably favorable safety profile across numerous animal studies, with no reported LD50 (lethal dose) even at very high concentrations. However, the absence of formal human clinical trials means that the long-term safety profile in humans remains unknown. The FDA has not approved BPC-157 for any indication.
Common
- β’ Injection site irritation or mild redness
- β’ Transient nausea (more common with oral administration)
- β’ Mild dizziness in initial doses
- β’ Temporary fatigue or drowsiness
- β’ Slight headache
- β’ Mild gastrointestinal discomfort
Serious / potential risks
- β’ No serious adverse events reported in published animal studies
- β’ Theoretical risk of promoting growth in existing tumors (not confirmed)
- β’ Unknown long-term effects in humans due to lack of clinical trials
- β’ Potential immunomodulatory effects with chronic use
- β’ Risk of contamination or mislabeling from unregulated sources
Drug interactions
Drug interaction data for BPC-157 is limited to animal studies and theoretical pharmacological considerations. The following interactions are based on known mechanistic pathways.
| Medication | Interaction | Recommendation |
|---|---|---|
| NSAIDs (Ibuprofen, Naproxen) | BPC-157 may counteract NSAID-induced gastric damage | Potentially protective; monitor GI symptoms |
| Anticoagulants (Warfarin, Heparin) | BPC-157 affects NO system and angiogenesis | Use with caution; monitor coagulation parameters |
| Dopaminergic drugs (L-DOPA) | BPC-157 modulates dopamine receptor sensitivity | May alter dopaminergic drug effects; consult physician |
| Corticosteroids | May counteract steroid-induced tissue atrophy | Potentially beneficial interaction; needs further study |
| Growth hormone / IGF-1 | BPC-157 upregulates GH receptor expression | May potentiate GH effects; use under medical supervision |
Storage & handling
Lyophilized (powder)
- β’ Store at -20Β°C to 4Β°C (freezer or refrigerator)
- β’ Protect from light and moisture
- β’ Stable for 12β24 months when stored properly
- β’ Keep in original sealed container until reconstitution
Reconstituted solution
- β’ Refrigerate at 2β8Β°C after reconstitution
- β’ Use bacteriostatic water for multi-dose reconstitution
- β’ Typical stability: 14β28 days refrigerated
- β’ Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $30β$60 per 5mg vial | Quality varies significantly; third-party testing recommended |
| Compounding pharmacies | $150β$300 per month | Prescription required; higher purity assurance |
| Clinical practitioners | $200β$500 per month | Includes medical supervision and monitoring |
| Oral capsules (research) | $50β$100 per month | Bioavailability may differ from injectable form |
The bottom line
BPC-157 is one of the most extensively studied regenerative peptides in preclinical research, with over 100 animal studies demonstrating tissue-healing effects across multiple organ systems. While the preclinical evidence is compelling, the lack of human clinical trials means its efficacy and safety in humans remain unconfirmed. It is not FDA-approved for any indication.
Best for
- β’ Researchers studying tissue regeneration and wound healing mechanisms
- β’ Individuals with chronic tendon or ligament injuries under medical supervision
- β’ Those exploring gut-healing protocols for GI conditions with practitioner guidance
- β’ Athletes recovering from musculoskeletal injuries under sports medicine oversight
Not for
- β’ Self-treatment without medical supervision
- β’ Individuals with active cancer or history of malignancy
- β’ Pregnant or breastfeeding women
- β’ Those expecting FDA-approved, clinically validated therapy
Related compounds
TB-500
Complementary regenerative peptide often stacked with BPC-157 for synergistic healing
GHK-Cu
Copper peptide with wound healing and collagen-stimulating properties
Thymosin Alpha-1
Immune-modulating peptide that complements BPC-157's tissue repair actions
KPV
Anti-inflammatory tripeptide often combined for gut-healing protocols
Frequently asked questions
References
- [1] Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des (2014). doi: 10.2174/13816128113199990421 PMID: 23590128
- [2] Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol (2016). doi: 10.2174/1570159X13666151013153422 PMID: 26592480
- [3] Chang CH, Tsai WC, Lin MS, et al.. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011). doi: 10.1152/japplphysiol.00945.2010 PMID: 21030672
- [4] Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels. Curr Pharm Des (2014). doi: 10.2174/13816128113199990421 PMID: 24001295
- [5] Kang EA, Han YM, An JM, et al.. BPC157 as potential agent rescuing from cancer cachexia. Curr Pharm Des (2018). doi: 10.2174/1381612824666180614082950 PMID: 29905118